Latest news about Procter & Gamble Health
Procter & Gamble Health
6,201.00
+92.50(+1.51%)
Company Performance:
View Company Insights1D+1.51%
1M+18.86%
6M+6.31%
1Y+7.85%
5Y+6.22%
More news about Procter & Gamble Health
06Apr 26
Procter & Gamble Health Limited Confirms Non-Large Corporate Status Under SEBI Framework
Procter & Gamble Health Limited disclosed to BSE and NSE that it does not qualify as a Large Corporate under SEBI's debt securities framework. The company reported nil outstanding borrowings as of March 31, 2026, and confirmed that credit rating requirements are not applicable. The disclosure was made in compliance with SEBI circulars regarding fund raising by large entities, with Company Secretary Zeal Rupani signing the formal notification on April 6, 2026.
06Apr 26
Procter & Gamble Health Limited Files Quarterly Compliance Certificate for Q4FY26
Procter & Gamble Health Limited filed its quarterly compliance certificate for Q4FY26 on April 6, 2026, confirming adherence to SEBI Regulation 74(5) requirements. The company's registrar, Kfin Technologies Limited, certified that all dematerialization details for the quarter ended March 31, 2026, were submitted to stock exchanges within prescribed timelines, demonstrating continued regulatory compliance.
27Mar 26
Procter & Gamble Health Limited Schedules Board Meeting for May 26, 2026 to Review FY26 Financial Results and Final Dividend
Procter & Gamble Health Limited has scheduled a board meeting for May 26, 2026, to consider audited financial statements for FY26 and evaluate final dividend recommendations. The company notified BSE and NSE on March 27, 2026, in compliance with SEBI Regulation 29, with the meeting agenda focusing on reviewing financial performance for the year ended March 31, 2026, and potential dividend distribution to shareholders.
06Feb 26
P&G Health Declares ₹160 Interim Dividend with February 12 Record Date
Procter & Gamble Health Limited's Board approved interim dividend of ₹160 per equity share for FY 2025-26, including a special dividend component of ₹50 per share. The company provided detailed TDS guidelines with varying rates for different shareholder categories and set February 10, 2026 as the deadline for document submission to avail appropriate tax rates.
06Feb 26
Procter & Gamble Health Q3FY26 Revenue Up 20.7% to ₹3,739M, Declares ₹160 Dividend
Procter & Gamble Health Limited announced Q3FY26 results showing strong revenue growth of 20.7% to ₹3,739 million but faced profitability pressures with net profit declining 14.7% to ₹776 million. The Board declared a substantial interim dividend of ₹160 per share including a special dividend component.
21Jan 26
Procter & Gamble Health Limited Board Meeting on February 6, 2026 to Consider Interim Dividend Declaration for FY26
Procter & Gamble Health Limited has revised its February 6, 2026 board meeting agenda to include consideration of interim dividend declaration for FY26. The company notified stock exchanges on January 21, 2026, through Company Secretary Zeal Rupani, referencing an earlier communication from December 26, 2025. This revision ensures regulatory compliance and keeps shareholders informed about potential dividend decisions.
05Nov 25
Procter & Gamble Health Reports 3% Sales Growth and 8% PAT Increase in Q2 FY2026
Procter & Gamble Health Limited (PGHL) announced strong Q2 FY2026 results, with revenue increasing 3% to ₹319.00 crores and net profit rising 8% to ₹89.00 crores compared to Q2 FY2025. Earnings per share grew by 7.40% to ₹53.34. The company's half-year performance showed revenue of ₹109.30 crores and net profit of ₹154.80 crores. PGHL's growth is attributed to strategic brand communication, product innovations like Livogen Iron Gummies, enhanced supply chain capabilities, and focused market approaches. The company maintains a strong liquidity position with cash and cash equivalents of ₹279.30 crores as of September 30, 2025.
16Sept 25
Procter & Gamble Health Limited Announces CFO Transition: Lokesh Chandak Steps Down, Shashank Srowthy to Take the Helm
Procter & Gamble Health Limited (P&G Health) has announced a change in its financial leadership. Current CFO Lokesh Chandak will resign effective September 30, 2025, moving to a new role within P&G. Shashank Srowthy, with 14 years of finance experience, will take over as CFO and Additional Executive Director from October 1, 2025, subject to regulatory approvals. The Board of Directors approved these changes in a meeting on September 16, 2025.
18Aug 25
Procter & Gamble Health Limited Secures Exchange Approval for Promoter Reclassification
Procter & Gamble Health Limited has received stock exchange approval to reclassify three former promoter shareholders as public shareholders. This change results in Procter & Gamble Overseas India BV becoming the sole promoter with a 51.82% stake, while public shareholders now hold 48.18%. The reclassification, initially applied for in June 2018 and effective from December 2018, has now received final approval from the stock exchange.
01Aug 25
Procter & Gamble Health Reports Strong Q1 Performance with Net Profit Surging to 662M Rupees
Procter & Gamble Health Limited (P&G Health) has announced impressive Q1 financial results. Net profit soared by 294% to ₹662.00 million, while revenue increased by 19.72% to ₹3,400.00 million. EBITDA grew by 87.15% to ₹903.00 million, with EBITDA margin expanding to 26.70% from 17.00%. The company, a major player in India's vitamins, minerals, and supplements sector, demonstrated strong growth across key metrics, indicating improved operational efficiency.
30Jul 25
P&G Hygiene Shares Surge as Quarterly Profit Doubles to ₹192 Crore
Procter & Gamble Health reported impressive Q2 results with net profit doubling to ₹192.00 crore from ₹81.00 crore year-over-year. Revenue marginally increased by 0.6% to ₹937.00 crore. EBITDA rose significantly to ₹266.00 crore, with EBITDA margin expanding to 28.4% from 12.7%. The stock price surged, reaching an intraday high of ₹14,540.00 (11.06% increase). Management attributed the strong performance to successful execution of their integrated growth strategy focusing on daily use categories and product superiority.
30May 25
Procter & Gamble Health Reports Q4 Profit Surge and Announces Dividend
Procter & Gamble Health's Q4 net profit rose 31.4% year-over-year to ₹612.00 million, while revenue increased 23% to ₹3.10 billion. However, net profit decreased 32.7% quarter-over-quarter. The company's board recommended a dividend of ₹45.00 per equity share.
29May 25
Procter & Gamble Health: Q3 Profit Surges 31%, ₹45 Dividend Proposed
Procter & Gamble Health announced impressive Q3 financial results. Net profit increased by 31.30% to ₹61.20 crore, while revenue grew by 23.20% to ₹311.00 crore. EBITDA rose by 20.20% to ₹81.00 crore. The company's board recommended a dividend of ₹45.00 per equity share. For the nine-month period, sales increased by 8.00% to ₹918.00 crore, and Profit After Tax grew by 27.00% to ₹234.00 crore.
28May 25
P&G India Misses Q3 Expectations, Long-Term Growth Remains Steady
Procter & Gamble Hygiene and Health Care Ltd (P&G India) reported disappointing Q3 results, falling short of market expectations. However, the company's long-term growth trajectory remains positive. P&G India has maintained a consistent revenue CAGR of 7.00% from FY19 to FY24, expected to continue through FY27E. Despite quarterly inconsistencies, annual performance shows steady growth. The company has improved its EBITDA margin by 250 basis points to approximately 23.50% over the FY19-FY24 period.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,780.10
(-0.47%)
6,596.50
(+0.30%)
4,339.90
(-0.65%)
1,398.70
(+1.71%)
1,084.60
(+0.74%)
1,267.50
(+0.33%)
2,249.80
(-0.50%)
2,353.00
(-0.70%)
1,463.60
(+1.61%)
1,427.20
(+2.36%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
